Related Experiment Videos
Amyloidosis
1Department of Medicine, Helsinki University Central Hospital, Finland.
Current Opinion in Rheumatology
|January 1, 1996
Summary
Rheumatic diseases can cause amyloidosis, leading to musculoskeletal issues. This review covers amyloid A, light-chain, and beta 2-microglobulin amyloidosis, detailing their causes, symptoms, diagnosis, and treatments for rheumatologists.
Area of Science:
- Rheumatology
- Immunology
- Biochemistry
Background:
- Amyloidosis is a significant complication of rheumatic diseases, often presenting with musculoskeletal symptoms.
- Understanding the diverse forms of amyloidosis, including amyloid A, amyloid light-chain, and amyloid beta 2-microglobulin, is crucial for effective management.
Purpose of the Study:
- To review current developments in amyloidosis associated with rheumatic diseases.
- To discuss the pathogenesis, clinical manifestations, diagnosis, and therapy of key amyloidosis subtypes from a rheumatologist's perspective.
Main Methods:
- Review of existing literature and clinical experience regarding amyloidosis in rheumatic diseases.
- Discussion of the biology of serum amyloid A (SAA) and development of new assays.
- Analysis of the role of modified beta 2-microglobulin in inflammation and bone resorption.
- Evaluation of serum amyloid P component scintigraphy for diagnosis and monitoring.
- Review of published guidelines for colchicine dosage in familial Mediterranean fever-associated amyloidosis.
- Assessment of intensive chemotherapy and stem cell transplantation for amyloid light-chain amyloidosis.
Main Results:
- The biology of serum amyloid A (SAA) has been elucidated, with new assays developed.
- Modified beta 2-microglobulin may trigger inflammatory responses leading to bone resorption in amyloid beta 2-microglobulin amyloidosis.
- Serum amyloid P component scintigraphy shows utility in diagnosis and monitoring.
- Colchicine dosage guidelines for familial Mediterranean fever-associated amyloidosis are available.
- Intensive chemotherapy and stem cell infusion show therapeutic promise for amyloid light-chain amyloidosis.
Conclusions:
- Amyloidosis presents a complex challenge in rheumatology, requiring a comprehensive understanding of its various forms.
- Advances in diagnostics and therapeutics, including novel assays, scintigraphy, and intensive chemotherapy regimens, offer improved management strategies.
- Further research into the pathogenic mechanisms and therapeutic interventions for amyloidosis in rheumatic diseases is warranted.